 Halozyme Therapeutics Inc. HALO, 1.20 stock fell in the extended session Tuesday after the biotech drug makers 2023 forecast disappointed Wall Street. Halozyme shares fell as much as 8 after hours, following a 1.2 gain to close the regular session at 55.70. 